Global Hemp Group Announces Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at MD Anderson Cancer Center, as Its Chief Scientific Advisor
Global Hemp Group Announces Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at MD Anderson Cancer Center, as Its Chief Scientific Advisor
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2023) - GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) ("GHG" or the "Company") is pleased to announce the appointment of Dr. Herbert Fritsche to the Company's Advisory Board as its Chief Scientific Advisor. Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of Texas MD Anderson Cancer Center for 41 years.
温哥华,不列颠哥伦比亚省-(Newsfile Corp.-2023年3月22日)-环球大麻集团公司。(CSE:GHG)(场外粉色:GBHPF)(法兰克福证券交易所:GHG)(“GHG”或“公司”)很高兴地宣布任命Herbert Fritsche博士为公司顾问委员会的首席科学顾问。Fritsche博士是世界知名的临床化学家,曾任德克萨斯大学MD安德森癌症中心临床化学科主任,曾任检验医学教授41年。
Dr. Fritsche served as an invited consultant/advisor to the Food and Drug Administration, the National Cancer Institute, the Laboratory Practice Guidelines Committee for the National Academy of Clinical Biochemistry, the Editorial Board of six international scientific journals, and as a consultant to many major international diagnostic companies. Previously, he served on the Expert Panel for developing Tumor Marker Practice Guidelines for the American Society of Clinical Oncology (ASCO) from its inception until his retirement from MD Anderson Cancer Center.
Fritsche博士曾担任食品和药物管理局、国家癌症研究所、国家临床生物化学研究院实验室实践指南委员会、六种国际科学期刊的编辑委员会的特邀顾问/顾问,以及许多大型国际诊断公司的顾问。在此之前,他一直担任美国临床肿瘤学会(ASCO)肿瘤标记物实践指南制定专家小组的成员,直到他从MD Anderson癌症中心退休。
His awards include the Johnson and Johnson Award for Outstanding Research and Contributions to Clinical Biochemistry from the National Academy of Clinical Biochemistry, the Abbott-ISOBM Award for Outstanding Research in Oncology, the Morton K. Schwartz Award for Outstanding Achievements in the field of Cancer Diagnostics from the American Association for Clinical Chemistry ("AACC"), the Carl Jolliff Award for Lifetime Achievements in Immunology and Immunodiagnostics from the Immunology Division of the AACC, the Morton K. Schwartz Award for significant contributions to the development of cancer diagnostics from the New York Metro Division of the AACC, the Outstanding Clinical Chemist Award by the Texas Section of the AACC, the National Award for Contributions in Education by the AACC, the Dean's Excellence Award from the University of Texas Graduate School of Biomedical Science, and the Distinguished Scientist Award from the Clinical Ligand Assay Society ("CLAS").
他的奖项包括美国国家临床生物化学学院颁发的Johnson and Johnson杰出研究和临床生物化学贡献奖、雅培-ISOBM肿瘤学杰出研究奖、美国临床化学协会(AACC)颁发的Morton K.Schwartz癌症诊断领域杰出成就奖、AACC免疫学部门颁发的Carl Jolliff免疫学和免疫诊断终身成就奖、AACC纽约Metro分部颁发的Morton K.Schwartz奖对癌症诊断发展的重大贡献、AACC得克萨斯州分部颁发的杰出临床化学家奖、AACC、得克萨斯大学生物医学研究生院颁发的院长杰出奖,以及临床配基检测学会(“CLAS”)颁发的杰出科学家奖。
Dr. Fritsche has served as President of the CLAS and various national committees for both the CLAS and AACC. He is a Fellow of the National Academy of Clinical Biochemistry.
Fritsche博士曾担任过中国科学院总裁以及中国科学院和美国医学会的多个全国委员会。他是美国国家临床生物化学研究院院士。
He has published over 200 peer-reviewed scientific papers, invited articles and book chapters, and participated in the validation and FDA clearance process for many commercial serum cancer markers currently in use in the United States. Dr. Fritsche holds three patents and two patents pending.
他发表了200多篇同行评议的科学论文,邀请了文章和书籍章节,并参与了美国目前使用的许多商业血清癌症标志物的验证和FDA批准过程。Fritsche博士拥有三项专利和两项正在申请的专利。
Dr. Fritsche has lectured extensively for many years at international and national meetings of medical and professional societies, and he is recognized internationally as an expert in the field of clinical chemistry, cancer diagnostics and laboratory medicine.
多年来,Fritsche博士在医学和专业学会的国际和国内会议上进行了广泛的演讲,他是国际公认的临床化学、癌症诊断和实验室医学领域的专家。
Dr Fritsche stated, "I am pleased to continue working with Stephen Barnhill, Jr. and I look forward to now working with him to expand GHG's efforts to sublicense the exclusively licensed unique intellectual property from Apollon Formularies, plc on the natural biologic pharmaceutical formulations for cancer, inflammatory diseases and chronic pain, thereby, increasing accessibility of these products to help patients around the world where they are legal."
弗里奇博士说:“我很高兴继续与小斯蒂芬·巴恩希尔合作,我期待着现在与他合作,扩大GHG公司的努力,从Apollon药方公司获得独家许可的独家知识产权,再授权给治疗癌症、炎症性疾病和慢性疼痛的天然生物药物配方,从而增加这些产品的可及性,帮助世界各地合法的患者。”
"Dr. Fritsche is a highly respected international authority in clinical chemistry and one of the world's leading experts on cancer biomarkers, whom I have had the honor of working with for more than 10 years. We are extremely pleased that he has agreed to join GHG's Advisory Board as our Chief Scientific Advisor ("CSA")," stated Stephen D. Barnhill, Jr. CEO of Global Hemp Group, "As GHG's CSA, Dr. Fritsche will be leading all scientific aspects of GHG's global licensing program for the intellectual property portfolio GHG recently licensed from Apollon."
小斯蒂芬·D·巴恩希尔说:“Fritsche博士是临床化学领域备受尊敬的国际权威人士,也是世界领先的癌症生物标记物专家之一,我有幸与他共事了10多年。我们非常高兴他同意加入GHG咨询委员会,担任我们的首席科学顾问。”作为GHG的CSA,Fritsche博士将领导最近从Apollon获得许可的GHG知识产权组合的全球许可计划的所有科学方面。
About Global Hemp Group Inc.
环球大麻集团公司简介
Global Hemp Group Inc. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) is focused on executing a multi-phased strategy to become a leader in the industrial hemp industry. To further support and innovate, GHG has established a R&D Division to actively pursue the development of Intellectual Property that can be patented for implementation at its projects and beyond. The Division is led by Prof. Víctor M. Castaño, Ph.D., whose career has focused in the areas of applied science and technology. The R&D team will initially focus on development of Environmentally Friendly Construction Materials, Nano Fertilizers and Enhanced Extraction from Hemp.
全球大麻集团公司(CSE:GHG)(场外交易市场代码:GBHPF)(FSE:GHG)专注于执行多阶段战略,以成为工业大麻行业的领导者。为了进一步支持和创新,GHG成立了一个研发部门,积极从事知识产权的开发,这些知识产权可以在其项目和其他项目中获得专利实施。该司由Víctor M.Castaño博士领导,他的职业生涯主要集中在应用科学和技术领域。研发团队最初将专注于开发环保建筑材料、纳米肥料和从大麻中强化提取。
Cautionary Note Regarding Forward-Looking Statements
有关前瞻性陈述的注意事项
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Global Hemp Group Inc., including, but not limited to, the impact of general economic conditions, industry conditions, volatility of commodity prices, currency fluctuations, dependence upon regulatory approvals, the availability of future financing and exploration risk, and the legality of cannabis and hemp. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of Page 2 of 2 preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Except as required by law, Global Hemp Group Inc. disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
本新闻稿中陈述的某些信息可能包含前瞻性陈述,这些陈述涉及大量已知和未知的风险和不确定性。这些前瞻性声明会受到许多风险和不确定性的影响,其中某些风险和不确定性是Global hemp Group Inc.无法控制的,包括但不限于总体经济状况、行业状况、大宗商品价格的波动、汇率波动、对监管部门批准的依赖、未来融资和勘探风险的获得以及大麻和大麻的合法性。请读者注意,编制此类信息时使用的假设虽然在编制第2页时被认为是合理的,但可能被证明是不准确的,因此不应过度依赖前瞻性陈述。除非法律另有要求,否则Global hemp Group Inc.无意更新或修改任何前瞻性陈述,以反映实际结果,无论是由于新信息、未来事件、假设的变化、影响此类前瞻性陈述的因素的变化或其他原因。
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
CSE未对本新闻稿的充分性或准确性进行审查,也不承担任何责任。
For Further Information Contact Global Hemp Group
欲了解更多信息,请联系环球大麻集团
Investor Relations
投资者关系
Tel: 778-726-2900 info@globalhempgroup.com
电话:778-726-2900
Subscribe to the GHG YouTube Channel:
订阅GHG YouTube频道:
Like us on Facebook:
就像我们在脸谱网上:
Follow us on Instagram:
在Instagram上关注我们:
Follow us on Twitter:
关注我们的推特:
Connect with us on LinkedIn:
在LinkedIn上与我们联系:
To view the source version of this press release, please visit
要查看本新闻稿的源版本,请访问